Key result
Key PAH therapies for Eisenmenger syndrome include ERAs, PDE5 inhibitors, and prostacyclin derivatives.
Why the study?
Do targeted PAH therapies (endothelin-receptor antagonists, phosphodiesterase type-5 inhibitors, prostacyclin derivatives) improve survival and functional capacity in patients with Eisenmenger syndrome compared to conventional therapy?
Do targeted PAH therapies (endothelin-receptor antagonists, phosphodiesterase type-5 inhibitors, prostacyclin derivatives) improve survival and functional capacity in patients with Eisenmenger syndrome compared to conventional therapy?
Targeted PAH therapies, including endothelin-receptor antagonists, PDE-5 inhibitors, and prostacyclin derivatives, improve survival and functional capacity in patients with Eisenmenger syndrome.
Supports targeted PAH therapy in Eisenmenger syndrome; hypothesis-generating pending randomized confirmation.
Eisenmenger syndrome (ES) is a complex and disastrous medical problem with profound cyanosis and clinical deterioration by significant right to left shunting. This syndrome is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart disease (PAH-CHD). Inverted shunt changes structures of pulmonary vasculature like all forms of PAH in ES (1). In the past, the management of patients with ES was limited to conventional therapy with an emphasis on regular informed cardiovascular follow-up. Subsequent clinical studies have made it possible to improve to patient survival and functional capacity. There are major therapeutic targets in PAH treatment using endothelin-receptor antagonists, phosphodiesterase type-5 inhibitors, and prostacyclin derivatives.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2016) conducted a review in Eisenmenger syndrome. Endothelin-receptor antagonists, phosphodiesterase type-5 inhibitors, and prostacyclin derivatives was evaluated. Therapeutic targets in pulmonary arterial hypertension treatment for Eisenmenger syndrome include endothelin-receptor antagonists, phosphodiesterase type-5 inhibitors, and prostacyclin derivatives.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: